Table 8

Exacerbation data

PlaceboSalbutamolSalmeterol
Number during each treatment period
Total979235
 Minor695820
 Major283415
Number of patients without exacerbations during each period (%)
Total72.173.584.98-151
 Minor76.676.889.58-151
 Major88.389.491.5
Corrected exacerbation rate (number per patient per year)
Total1.37 (1.11 to 1.67)1.39 (1.12 to 1.71)0.518-159 (0.35 to 0.70)
 Minor0.97 (0.76 to 1.23)0.88 (0.67 to 1.13)0.298-159 (0.18 to 0.45)
 Major0.40 (0.26 to 0.57)0.51 (0.36 to 0.72)0.228-152(0.12 to 0.36)
Mean duration per exacerbation (days)
Total4.4 (3.6 to 5.2)4.5 (3.8 to 5.2)3.6 (2.6 to 4.6)
 Minor4.0 (3.4 to 4.7)3.7 (3.0 to 4.4)2.8 (2.3 to 3.3)
 Major5.4 (3.2 to 7.6)5.8 (4.5 to 7.1)4.7 (2.7 to 6.8)
Mean time spent in exacerbation per patient (days)
Total10.0 (7.2 to 12.8)10.3 (6.1 to 14.5)5.5 (2.8 to 8.2)
 Minor7.7 (5.5 to 9.9)6.2 (4.6 to 7.8)3.5 (2.2 to 4.6)
 Major8.4 (5.2 to 11.6)12.38-150 (4.2 to 20.4)5.5 (1.8 to 9.3)
  • Figures in brackets are 95% confidence intervals.

  • 8-150 p = 0.02, salbutamol longer than placebo.

  • 8-151 p = 0.009, salmeterol better than placebo (both results).

  • 8-152 p = 0.03, salmeterol lower than placebo.

  • 8-159 p = 0.0001, salmeterol lower than placebo.